Evidence map›Paper›PMID 20610561›Full record

ArticleEndocrinology2010

Modulation of prohormone convertase 1/3 properties using site-directed mutagenesis.

Akihiko Ozawa, Juan R Peinado, Iris Lindberg

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Akihiko OzawaDepartment of Anatomy and Neurobiology, University of Maryland, Baltimore, 20 Penn Street, Health Sciences Facility II Room S251, Baltimore, Maryland 21201, USA.
Juan R Peinado
Iris Lindberg
University of Maryland, Baltimore · USUniversity of Córdoba · ES

Funding

OPIOID PEPTIDE SYNTHESIZING ENZYMESR01DA005084 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI LINDBERG, IRIS · 1988 to 2014
$4.4M
Opioid Peptide Synthesizing EnzymesR56DA005084 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI LINDBERG, IRIS · 2016 to 2016
$174k
NIDA NIH HHS R01 DA005084NIDA NIH HHS R56 DA005084PHS HHS NIDA05084-22
6 · The paper itself

Abstract

Prohormone convertase (PC)1/3 and PC2 cleave active peptide hormones and neuropeptides from precursor proteins. Compared with PC2, recombinant PC1/3 exhibits a very low specific activity against both small fluorogenic peptides and recombinant precursors, even though the catalytic domains in mouse PC1/3 and PC2 share 56% amino acid sequence identity. In this report, we have designed PC2-specific mutations into the catalytic domain of PC1/3 in order to investigate the molecular contributions of these sequences to PC1/3-specific properties. The exchange of residues RQG(314) with the SY sequence present in the same location within PC2 paradoxically shifted the pH optimum of PC1/3 upward into the neutral range; other mutations in the catalytic domain had no effect. Although none of the full-length PC1/3 mutants examined exhibited increased specific activity, the 66-kDa form of the RQG(314)SY mutant was two to four times more active than the 66-kDa form of wild-type PC1/3. However, stable transfection of RQG(314)SY into PC12 cells did not result in greater activity against the endogenous substrate proneurotensin, implying unknown cellular controls of PC1/3 activity. Mutation of GIVTDA(243-248) to QPFMTDI, a molecular determinant of 7B2 binding, resulted in increased zymogen expression but no propeptide cleavage or secretion, suggesting that this mutant is trapped in the endoplasmic reticulum due to an inability to cleave its own propeptide. We conclude that many convertase-specific properties are attributable less to convertase-specific catalytic cleft residues than to convertase-specific domain interactions.

Indexed as

Amino Acid SequenceAnimalsBinding SitesBlotting, WesternCatalytic DomainCell LineEnzyme AssaysHumansHydrogen-Ion ConcentrationMiceModels, MolecularMolecular Sequence DataMutagenesis, Site-DirectedMutant ProteinsNeurotensinPC12 CellsMutant ProteinsNeurotensinproneurotensinProprotein Convertase 1Proprotein Convertase 2Protein Precursors

Identifiers

PMID20610561
PMCPMC2940488
OpenAlexW1976572038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.